Table 2. Correlation between cycle numbers of neoadjuvant chemotherapy/targeted therapy and clinicopathologic features in 64 metastatic colorectal cancer patients.
| Total | Cycle = 6 | Cycle ≥ 7 | Chi square/T statistic | p-value | |
|---|---|---|---|---|---|
| N = 64 (%) | N = 28 (%) | N = 36 (%) | |||
| Age, years ≧65 years <65 years |
28 (43.8) 36 (56.2) |
12(42.9) 16 (57.1) |
16 (44.4) 20 (55.6) |
0.016 | 1.000 |
| Gender Male Female |
40 (62.5) 24 (37.5) |
19 (67.9) 9 (32.1) |
21 (58.3) 15 (41.7) |
0.610 | 0.603 |
| Metastectomy location Liver Lung Ovary |
46 (71.9) 15 (23.4) 3 (4.7) |
23 (82.1) 5 (17.9) 0 |
23 (63.9) 10 (27.8) 3 (8.3) |
3.725 | 0.155 |
| Primary tumor location Right-side Left-side |
7 (10.9) 57 (89.1) |
3 (10.7) 25 (89.3) |
4 (11.1) 32 (88.9) |
0.003 | 1.000 |
| Synchronous/Metachronous Synchronous Metachronous |
36 (56.2) 28 (43.8) |
18 (64.3) 10 (35.7) |
18 (50.0) 18 (50.0) |
1.306 | 0.314 |
| Operation Operation time (min, medium + SD) Estimated blood loss (ml, medium + SD) |
150 + 109.73 100 + 154.73 |
200 + 137.45 200 + 199.28 |
160 + 80.67 90 + 116.32 |
2.271 2.429 |
0.027* 0.019* |
|
RAS status Wild Mutant |
53 (82.8) 11 (17.2) |
22 (78.6) 6 (21.4) |
31 (86.1) 5 (13.9) |
0.6290 | 0.513 |
| Pre-treatment CEA (ng/ml) ≧5 <5 Post-treatment CEA (ng/ml) ≧5 <5 |
45 (70.3) 19 (29.7) 28 (43.8) 36 (56.2) |
19 (67.9) 9 (32.1) 15 (53.6) 13 (46.4) |
26 (72.2) 10 (27.8) 13 (36.1) 23 (63.9) |
0.144 1.951 |
0.786 0.207 |
| Targeted agents Cetuximab Bevacizumab |
39 (60.9) 25 (39.1) |
17 (60.7) 11 (39.3) |
22 (61.1) 14 (38.9) |
0.001 | 1.000 |
| Efficacy Response (CR + PR) Non-response (SD + PD) |
47 (73.4) 17 (26.6) |
15 (53.6) 13 (46.4) |
32 (88.9) 4 (11.1) |
10.071 | 0.004* |
| Progression Yes No |
35 (54.7) 29 (45.3) |
20 (71.4) 8 (28.6) |
15 (41.7) 21 (58.3) |
5.630 | 0.024* |
| Survival Yes No |
41 (64.1) 23 (35.9) |
13 (46.4) 15 (53.6) |
28 (77.8) 8 (22.2) |
6.723 | 0.017* |
| Grade III or more adverse effect Yes No |
10 (15.6) 54 (84.4) |
2 (7.1) 26 (92.9) |
8 (22.2) 28 (77.8) |
2.717 | 0.165 |
Notes: CEA = carcinoembryonic antigen; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.
*p-value < 0.05.